Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.
Panagiotis A KonstantinopoulosSu-Chun ChengElizabeth K LeeAlexandre Andre Balieiro Anastacio da CostaDoga C GulhanAndrea E Wahner HendricksonBose S KochupurakkalDavid L KolinElise C KohnJoyce F LiuRichard T PensonElizabeth H StoverJennifer CurtisHannah SawyerMadeline PolakDipanjan ChowdhuryAlan D' AndreaAnniina FärkkiläGeoffrey I ShapiroUrsula A MatulonisPublished in: JCO precision oncology (2024)
The results of this follow-up analysis continue to support the promise of combined gemcitabine/ATRi therapy in platinum resistant ovarian cancer, an active area of investigation with several ongoing clinical trials.
Keyphrases
- phase ii study
- open label
- locally advanced
- clinical trial
- placebo controlled
- phase ii
- double blind
- phase iii
- rectal cancer
- squamous cell carcinoma
- study protocol
- big data
- randomized controlled trial
- stem cells
- free survival
- oxidative stress
- bone marrow
- artificial intelligence
- dna repair
- dna damage
- mesenchymal stem cells
- replacement therapy